Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 3/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771568 | 0.94 | TACR1 (0.34) | NPY1RSCN9ATACR1 | |
| SCHEMBL6763129 | 0.87 | KMT2A (0.42) | NPY1RSCN9AKMT2AL3MBTL1DRD2 | |
| SCHEMBL3780570 | 0.80 | NPY1R (0.38) | NPY1RSCN9AKMT2AL3MBTL1 | |
| SCHEMBL6762670 | 0.79 | AADAT (0.39) | NPY1RKMT2ADRD2 | |
| SCHEMBL6763949 | 0.79 | BACE1 (0.39) | NPY1RKMT2A | |
| SCHEMBL6763249 | 0.76 | EPHX2 (0.41) | NPY1RSCN9ADRD2 | |
| SCHEMBL6763244 | 0.75 | PYGL (0.35) | NPY1RSCN9ADRD2 | |
| SCHEMBL6832201 | 0.74 | BACE1 (0.41) | NPY1RKMT2A | |
| SCHEMBL6762742 | 0.74 | BACE1 (0.41) | NPY1RKMT2A | |
| SCHEMBL6762623 | 0.74 | BACE1 (0.41) | NPY1RKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | NPY1R 499/4885SCN9A 1463/4885KMT2A 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.